Exploring Cross-Sectional and Longitudinal Associations Among DNA Methylation, Prognostic Proteins, and Symptoms in Patients Prescribed Oral Anticancer Medications for Multiple Myeloma
Open Access
- 8 October 2026
- journal article
- Published by SAGE Publications in Biological Research For Nursing
Abstract
At-home administration of oral anticancer medications (OAM) limits interactions with healthcare providers, therefore limiting opportunities for symptom management, posing threats to medication adherence. Individuals diagnosed with multiple myeloma (MM) experience symptoms from both disease- and treatment-related factors. Proteins Beta-2 Microglobulin (B2M) and Lactate Dehydrogenase (LDH) are routinely used in disease monitoring, yet their associations with symptoms and regulation via DNA methylation (DNAm) in individuals with MM have not been investigated. This study explored relationships among LDH and B2M proteins; DNAm of genes B2M, LDHA, LDHB ; and symptoms in patients prescribed OAMs for MM. This was a 6-month, longitudinal, exploratory analysis. Symptoms were assessed using self-reported measures. Protein levels were extracted from medical records. DNAm of B2M, LDHA, and LDHB promoter regions were quantified via pyrosequencing of peripheral blood samples. Linear mixed modeling explored cross-sectional and longitudinal associations. Significant cross-sectional associations were identified between fatigue, LDHA and B2M DNAm, and B2M protein ( p < .02); pain and LDHA and B2M DNAm ( p < .05); gastrointestinal disturbances and LDHA DNAm and LDH protein ( p < .05); shortness of breath and LDHA DNAm ( p < .04); and depression and LDH protein ( p < .04). Longitudinal interaction effects were significant for B2M DNAm and fatigue ( p < .05), LDHA and B2M DNAm and pain ( p < .04), and LDH protein and depression ( p < .04). Prognostic proteins B2M and LDH and their gene-level DNAm patterns were significantly associated with symptoms in individuals taking OAMs for MM. These preliminary findings support further exploration of multi-omics pathways underlying symptoms to inform symptom identification and management strategies.Keywords
Funding Information
- National Institute of Nursing Research (K23NR019296)
- National Institute of Nursing Research (T32NR009759)
- Achievement Rewards for College Scientists (ARCS) Pittsburgh Chapter
- K. Leroy Irvis Fellowship at the University of Pittsburgh
- Center for Research and Evaluation Pilot/Feasibility Study Program at the University of Pittsburgh
- Supporting Our Scientists Award, funded by The Doris Duke Foundation, in partnership with the University of Pittsburgh and the American Heart Association
This publication has 40 references indexed in Scilit:
- Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018JAMA Internal Medicine, 2021
- Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment optionsBlood Reviews, 2021
- β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progressionImmunity, 2021
- Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)Annals of Hematology, 2021
- Symptom burden and its functional impact in patients with “symptomatic” relapsed or refractory multiple myelomaSupportive Care in Cancer, 2020
- Treatment and disease‐related complications in multiple myeloma: Implications for survivorshipAmerican Journal of Hematology, 2020
- Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple MyelomaTransplantation and Cellular Therapy, 2018
- Anxiety and Depression in Cancer SurvivorsMedical Clinics of North America, 2017
- Treatment-related symptom management in patients with multiple myeloma: a reviewSupportive Care in Cancer, 2015
- The EORTC Core Quality of Life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapyEuropean Journal of Cancer, 1995